Trials / Withdrawn
WithdrawnNCT04756791
Prospective Comparison of Single-Injection Serratus Anterior Plane Block With Ropivacaine Versus Local Infiltration of Anaesthetic After Breast Surgery
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Universitair Ziekenhuis Brussel · Academic / Other
- Sex
- Female
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate whether a serratus anterior plane block (SAPB) is more effective than a local infiltration anesthesia (LIA) with an equal dose and same anesthetic performed by the surgeon, as an adjuvant to treat postoperative pain after unilateral mastectomy.
Detailed description
To evaluate whether a serratus anterior plane block (SAPB) is more effective than a local infiltration anesthesia (LIA) with an equal dose and same anesthetic performed by the surgeon, as an adjuvant to treat postoperative pain after unilateral mastectomy. Primary endpoint: the use of opioid's in the postoperative period. Secondary endpoint: Numerical Pain Rating Scale (NPRS) score recorded at the 2nd, 8th, 16th, 24th hour after surgery. 0 means no pain and 10 is the worst pain imaginable. In addition at the same time, we will look to the degree of arm mobilization where there will be 3 possible groups: 1. restricted, 2. fair mobilization and 3. free mobilization. There are 2 treatment arms: 1st arm is the standard therapy, namely the local infiltration anesthesia. 2nd arm is the experimental arm, namely the SAPB. Patients are randomised into each arm after screening.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | SAPB | local anesthetic is injected between the serratus anterior and latissimus dorsi muscles. |
| PROCEDURE | Local Injection Anesthesia | Anesthesia is injected directly into the tissue that is will be numbing. |
Timeline
- Start date
- 2021-06-16
- Primary completion
- 2023-12-31
- Completion
- 2024-12-31
- First posted
- 2021-02-16
- Last updated
- 2025-12-18
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT04756791. Inclusion in this directory is not an endorsement.